A Phase 3 interventional study of GW-1000-02 and GW-2000-02 in Pain, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-10.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing nabiximols in Pain — none open to participants now, none under way, none of them phase 3. nabiximols · Pain.
Among the 17 studies testing nabiximols in Pain, this one is the 15th largest by enrollment, is the only one that started in 2001, is one of 15 in phase 3, and was the 16th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 17 studies testing nabiximols in Pain is open now. The open studies under Pain, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2001.
This study's enrollment of 48 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 246 across the 17 interventional studies. Of the 16 that completed or were terminated, 16 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 17 have an industry lead sponsor. The 3 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
20 studies in Pain by Jazz Pharmaceuticals: none open now, none under way, none of them phase 3. Of 20 finished, 20 (100%) have results posted.
Among the 20 studies in Pain by Jazz Pharmaceuticals, this one is the 18th largest by enrollment, is the only one that started in 2001, is one of 18 in phase 3, and was the 20th registered.
Jazz Pharmaceuticals’s Pain studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing nabiximols in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jazz Pharmaceuticals’s 20 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to compare the efficacy of two sublingual cannabinoid based medicine extracts with placebo in the treatment of chronic pain due to brachial plexus injury.
This study used a three way crossover study design. Eligible patients recorded their symptoms during a one to two week baseline period, then entered a three period, double blind, randomised crossover of GW-1000-02, GW-2000-02 and placebo. Each period lasted two weeks, with no washout between periods. There were six possible treatment sequences. The primary analysis was based on Box Scale-11 pain severity scores recorded throughout the study in patient daily diary booklets. Blood samples were taken from patient-volunteers at the beginning of each period, for measurement of plasma cannabinoid concentration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active treatment.
Drug: GW-1000-02
Active treatment.
Drug: GW-2000-02
Placebo control.
Drug: Placebo
Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
Also known as: Sativex
Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
Change From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days)
Each day patients recorded in their patient diary, the severity of their pain during the previous 24 hours using a Box Scale-11 pain score ranging from zero "no pain at all" to 10 "pain as bad as you can imagine". The Box Scale-11 pain score endpoint for each assessment period was the average of all available data recorded during the seven whole days prior to the visit immediately subsequent to that period, but only including data from Day 8 onwards. A negative value indicates an improvement in pain score from baseline.
Time frame: Up to 74 days
Change From Baseline in the Mean Sleep Disturbance Score at the End of Each Treatment Period (Each Lasting 14-20 Days).
Each day patients recorded in their patient diary the number of times they were woken due to pain during the previous night. The results were recorded as "None", "Once", "Twice" and "More Than Twice" and converted to a four point scale, zero to three respectively. The treatment days and the assessment periods were defined in the same way as for the Box Scale-11 pain score. A negative value indicates an improvement from baseline.
Time frame: Up to 74 days
Change From Baseline in the Mean Box Scale-11 Sleep Quality Score at the End of Each Treatment Period (Each Lasting 14-20 Days).
Each day patients recorded in their patient diary the quality of their sleep during the previous night using a Box Scale-11 sleep score ranging from zero "Worst Imaginable" to 10 "Best Imaginable". The treatment days and the assessment periods were defined in the same way as for the Box Scale-11 pain score. A positive value indicates an improvement from baseline.
Time frame: Up to 74 days
Change From Baseline in the Mean McGill Pain Questionnaire Part 1 Score for 'Total Pain Intensity' at the End of Each Treatment Period (Each Lasting 14-20 Days)
Part 1 of the questionnaire related to the intensity of 15 different types of pain. Intensity was recorded separately for each type of pain on a zero to three scale, where zero = "None", one = "Mild", two = "Moderate" and three = "Severe". The total intensity was defined as the unweighted sum of the 15 scores, giving a minimum possible score of zero (lowest pain score) and a maximum possible score of 45 (highest pain score). The distribution of each of the 15 types of pain was summarised at baseline and for each treatment. A negative value indicates an improvement in pain from baseline.
Time frame: Up to 74 days
Change From Baseline in the Mean McGill Pain Questionnaire Part 2 Score for 'Intensity of Pain' at the End of Each Treatment Period (Each Lasting 14-20 Days)
Part 2 of the questionnaire recorded the intensity of pain at present. Results were recorded on a VAS ranging from zero "No pain" to 100 "Worst possible pain". Intensity of pain was summarised and analysed in the same manner as the primary efficacy parameter of Box Scale-11 pain score. A negative value indicates an improvement from baseline.
Time frame: Up to 74 days
Change From Baseline in the Number of Patients Who Reported 'No Pain' or 'Mild Pain' Using a McGill Pain Questionnaire Part 3 Score for 'Strength of Pain at Present' at the End of Each Treatment Period (Each Lasting 14-20 Days)
Part 3 of the questionnaire recorded the strength of pain at present. Results were recorded in six categories which were classified as "No Pain", "Mild", "Discomforting", "Distressing", "Horrible" and "Excruciating". The change from baseline in the number of patients who reported "No Pain" or "Mild Pain" at the end of the respective treatment periods is presented. An increase in number indicates an improvement from baseline.
Time frame: Up to 74 days
Change From Baseline in the Mean Pain Disability Index Score at the End of Each Treatment Period (Each Lasting 14-20 Days).
The Pain Disability Index consisted of seven assessments representing different aspects of disability due to pain. Each assessment was scored on a zero to 10 scale, where zero equated with "no disability" and 10 equated with "total disability". The total Pain Disability Index score was the unweighted sum of the seven pain scores, ranging from zero to 70. A negative value indicates an improvement from baseline.
Time frame: Up to 74 days
Change From Baseline in the Mean 12-Item General Health Questionnaire Score at the End of Each Treatment Period (Each Lasting 14-20 Days).
The 12-Item General Health Questionnaire consisted of 12 general health questions. Each question was scored on a zero to three scale, where zero represented the better assessment. The total score was the unweighted sum of the 12 scores, ranging from zero to 36. A negative value indicates an improvement from baseline.
Time frame: Up to 74 days
Incidence of Adverse Events as a Measure of Patient Safety.
The number of patients who experienced an adverse event during the course of study is presented.
Time frame: Up to 114 days
| Milestone | GW-1000-02 First, Then GW-2000-02, Then Placebo | GW-2000-02 First, Then GW-1000-02, Then Placebo | Placebo First, Then GW-1000-02, Then GW-2000-02 | GW-1000-02 First, Then Placebo, Then GW-2000-02 | Placebo First, Then GW-2000-02, Then GW-1000-02 | GW-2000-02 First, Then Placebo, Then GW-1000-02 |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | GW-1000-02 First, Then GW-2000-02, Then Placebo | GW-2000-02 First, Then GW-1000-02, Then Placebo | Placebo First, Then GW-1000-02, Then GW-2000-02 | GW-1000-02 First, Then Placebo, Then GW-2000-02 | Placebo First, Then GW-2000-02, Then GW-1000-02 | GW-2000-02 First, Then Placebo, Then GW-1000-02 |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 | 8 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | GW-1000-02 First, Then GW-2000-02, Then Placebo | GW-2000-02 First, Then GW-1000-02, Then Placebo | Placebo First, Then GW-1000-02, Then GW-2000-02 | GW-1000-02 First, Then Placebo, Then GW-2000-02 | Placebo First, Then GW-2000-02, Then GW-1000-02 | GW-2000-02 First, Then Placebo, Then GW-1000-02 |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 7 |
| Completed | 8 | 8 | 8 | 8 | 8 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
Each day patients recorded in their patient diary, the severity of their pain during the previous 24 hours using a Box Scale-11 pain score ranging from zero "no pain at all" to 10 "pain as bad as you can imagine". The Box Scale-11 pain score endpoint for each assessment period was the average of all available data recorded during the seven whole days prior to the visit immediately subsequent to that period, but only including data from Day 8 onwards. A negative value indicates an improvement in pain score from baseline.
| units on a scale | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Change From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days) | -0.6 ± 1.13 | -0.6 ± 1.34 | 0.0 ± 1.23 |
Each day patients recorded in their patient diary the number of times they were woken due to pain during the previous night. The results were recorded as "None", "Once", "Twice" and "More Than Twice" and converted to a four point scale, zero to three respectively. The treatment days and the assessment periods were defined in the same way as for the Box Scale-11 pain score. A negative value indicates an improvement from baseline.
| units on a scale | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Change From Baseline in the Mean Sleep Disturbance Score at the End of Each Treatment Period (Each Lasting 14-20 Days). | -0.2 ± 0.43 | -0.4 ± 0.51 | 0.0 ± 0.47 |
Each day patients recorded in their patient diary the quality of their sleep during the previous night using a Box Scale-11 sleep score ranging from zero "Worst Imaginable" to 10 "Best Imaginable". The treatment days and the assessment periods were defined in the same way as for the Box Scale-11 pain score. A positive value indicates an improvement from baseline.
| units on a scale | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Change From Baseline in the Mean Box Scale-11 Sleep Quality Score at the End of Each Treatment Period (Each Lasting 14-20 Days). | 0.9 ± 1.22 | 1.2 ± 1.39 | 0.4 ± 1.40 |
Part 1 of the questionnaire related to the intensity of 15 different types of pain. Intensity was recorded separately for each type of pain on a zero to three scale, where zero = "None", one = "Mild", two = "Moderate" and three = "Severe". The total intensity was defined as the unweighted sum of the 15 scores, giving a minimum possible score of zero (lowest pain score) and a maximum possible score of 45 (highest pain score). The distribution of each of the 15 types of pain was summarised at baseline and for each treatment. A negative value indicates an improvement in pain from baseline.
| units on a scale | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Change From Baseline in the Mean McGill Pain Questionnaire Part 1 Score for 'Total Pain Intensity' at the End of Each Treatment Period (Each Lasting 14-20 Days) | -3.2 ± 8.91 | -3.8 ± 9.37 | -1.8 ± 9.26 |
Part 2 of the questionnaire recorded the intensity of pain at present. Results were recorded on a VAS ranging from zero "No pain" to 100 "Worst possible pain". Intensity of pain was summarised and analysed in the same manner as the primary efficacy parameter of Box Scale-11 pain score. A negative value indicates an improvement from baseline.
| units on a scale | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Change From Baseline in the Mean McGill Pain Questionnaire Part 2 Score for 'Intensity of Pain' at the End of Each Treatment Period (Each Lasting 14-20 Days) | -14.9 ± 25.15 | -17.3 ± 26.74 | -8.0 ± 26.92 |
Part 3 of the questionnaire recorded the strength of pain at present. Results were recorded in six categories which were classified as "No Pain", "Mild", "Discomforting", "Distressing", "Horrible" and "Excruciating". The change from baseline in the number of patients who reported "No Pain" or "Mild Pain" at the end of the respective treatment periods is presented. An increase in number indicates an improvement from baseline.
| participants | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Change From Baseline in the Number of Patients Who Reported 'No Pain' or 'Mild Pain' Using a McGill Pain Questionnaire Part 3 Score for 'Strength of Pain at Present' at the End of Each Treatment Period (Each Lasting 14-20 Days) | 4 | 4 | 3 |
The Pain Disability Index consisted of seven assessments representing different aspects of disability due to pain. Each assessment was scored on a zero to 10 scale, where zero equated with "no disability" and 10 equated with "total disability". The total Pain Disability Index score was the unweighted sum of the seven pain scores, ranging from zero to 70. A negative value indicates an improvement from baseline.
| units on a scale | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Change From Baseline in the Mean Pain Disability Index Score at the End of Each Treatment Period (Each Lasting 14-20 Days). | -5.3 ± 9.97 | -3.1 ± 10.37 | -3.6 ± 7.69 |
The 12-Item General Health Questionnaire consisted of 12 general health questions. Each question was scored on a zero to three scale, where zero represented the better assessment. The total score was the unweighted sum of the 12 scores, ranging from zero to 36. A negative value indicates an improvement from baseline.
| units on a scale | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Change From Baseline in the Mean 12-Item General Health Questionnaire Score at the End of Each Treatment Period (Each Lasting 14-20 Days). | -2.2 ± 6.70 | -1.2 ± 6.12 | 0.1 ± 3.92 |
The number of patients who experienced an adverse event during the course of study is presented.
| participants | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| Incidence of Adverse Events as a Measure of Patient Safety. | 34 | 37 | 20 |
Collected over All adverse events occurring from the study onset to up to 40 days follow-up (up to 114 days) were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GW-1000-02 | — | 1/46 (2.2%) | 34/46 (73.9%) |
| GW-2000-02 | — | 0/47 (0%) | 37/47 (78.7%) |
| Placebo | — | 0/48 (0%) | 20/48 (41.7%) |
| Event | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/46 | 0/47 | 0/48 |
| Event | GW-1000-02 | GW-2000-02 | Placebo |
|---|---|---|---|
| DizzinessNervous system disorders | 9/46 | 11/47 | 4/48 |
| DysgeusiaNervous system disorders | 10/46 | 5/47 | 0/48 |
| SomnolenceNervous system disorders | 7/46 | 6/47 | 5/48 |
| Headache Not Otherwise SpecifiedNervous system disorders | 0/46 | 5/47 | 0/48 |
| NauseaGastrointestinal disorders | 0/46 | 5/47 | 3/48 |
| Feeling DrunkGeneral disorders | 4/46 | 4/47 | 0/48 |
| Pain ExacerbatedGeneral disorders | 0/46 | 4/47 | 0/48 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 2/46 | 4/47 | 0/48 |
| Oral DiscomfortGastrointestinal disorders | 0/46 | 0/47 | 4/48 |
| Dry MouthNervous system disorders | 3/46 | 3/47 | 0/48 |
| Age, Categorical(Participants) | All Study Treatments: GW-1000-02, GW-2000-02 and Placebo |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 48 |
| >=65 years | 0 |
| Age, Continuous(years) | All Study Treatments: GW-1000-02, GW-2000-02 and Placebo |
|---|---|
| Mean | 38.53 ± 10.342 |
| Sex: Female, Male(Participants) | All Study Treatments: GW-1000-02, GW-2000-02 and Placebo |
|---|---|
| Female | 2 |
| Male | 46 |
| Region of Enrollment(participants) | All Study Treatments: GW-1000-02, GW-2000-02 and Placebo |
|---|---|
| United Kingdom | 48 |
The record gives a start of Dec 2001, a primary completion of Sep 2002 and a completion of Sep 2002. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 10 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nabiximols